Celularity Inc. Class A (CELU)
$1.63
$-0.47
(-22.41%)
As on 28-Aug-2026 13:40EDT
Market cap
$23 Mln
Revenue (TTM)
$19 Mln
P/E Ratio
--
P/B Ratio
9.9
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-63.7 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-36.8
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-3.7
-
Face value
--
-
Shares outstanding
28,945,961
6 Years Aggregate
CFO
$-436.16 Mln
EBITDA
$-305.20 Mln
Net Profit
$-469.69 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Celularity Inc. Class A (CELU)
| 46.8 | 117.0 | 78.1 | -57.1 | -18.3 | -54.3 | -- |
|
BSE Sensex
| -8.8 | 0.6 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|---|---|
|
Celularity Inc. Class A (CELU)
| -46.6 | -15.7 | -80.9 | -74.8 | -53.5 | 10.6 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Celularity Inc. Class A (CELU)
|
1.6 | 23.2 | 19.2 | -96.3 | -351.8 | -- | -- | 9.9 |
| 84.9 | 12,304.7 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.4 | |
| 246.7 | 16,614.0 | 1,054.4 | 755.9 | 5.7 | -- | 19.4 | 10.1 | |
| 72.3 | 10,682.6 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 54.2 | 13,400.0 | 2,435.9 | 860.6 | 31.0 | 43 | 17 | 7.3 | |
| 105.3 | 12,277.1 | 1,663.7 | 413.6 | 36.3 | 430 | 31.2 | 83.9 | |
| 350.5 | 10,258.4 | 440.5 | 241.5 | 33.4 | 18.7 | 42.2 | 7.3 | |
| 534.5 | 11,938.8 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 22.9 | |
| 603.9 | 17,326.2 | 2,782.3 | 491.5 | 21.1 | 110.1 | 36.5 | 39.4 | |
| 348.4 | 10,496.2 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 |
Shareholding Pattern
View DetailsAbout Celularity Inc. Class A (CELU)
Celularity Inc., a cellular and regenerative medicine company, focuses on addressing aging-related disease using novel therapies. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It develops... off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. Its therapeutic programs include PDA-001 for the treatment of autoimmune (Crohn's) and degenerative disease; and PDA-002 for treating multiple sclerosis, rheumatoid arthritis, stroke, and diabetic peripheral neuropathy. The company also produces, sells, and licenses products used in surgical and wound care markets, such as Biovance, Biovance 3L, Rebound, Interfyl, and Centaflex; and collects, processes, and stores umbilical cord and placental blood and tissue after full-term pregnancies under the LifebankUSA brand. Celularity Inc. has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. Celularity Inc. was founded in 1998 and is headquartered in Florham Park, New Jersey. Read more
-
Founder, CEO & Chairman
Dr. Robert Joseph Hariri M.D., Ph.D.
-
Founder, CEO & Chairman
Dr. Robert Joseph Hariri M.D., Ph.D.
-
Headquarters
Florham Park, NJ
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Celularity Inc. Class A (CELU)
What is the current share price of Celularity Inc Class A (CELU) Today?
The share price of Celularity Inc Class A (CELU) is $1.63 (NASDAQ) as of 28-Aug-2026 13:40 EDT. Celularity Inc Class A (CELU) has given a return of -18.27% in the last 3 years.
What is the current PB & PE ratio of Celularity Inc Class A (CELU)?
Since, TTM earnings of Celularity Inc Class A (CELU) is negative, P/E ratio is not available.
The P/B ratio of Celularity Inc Class A (CELU) is 9.89 times as on 21-Aug-2026, a 85 premium to its peers’ median range of 5.35 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-0.35 |
-0.84 |
2024 |
-0.81 |
5.31 |
2023 |
-0.02 |
0.11 |
2022 |
1.35 |
0.10 |
2021 |
-0.63 |
0.64 |
What is the 52 Week High and Low of Celularity Inc Class A (CELU)?
The 52-week high and low of Celularity Inc Class A (CELU) are Rs 4.00 and Rs 0.56 as of 29-Aug-2026.
What is the market cap of Celularity Inc Class A (CELU)?
Celularity Inc Class A (CELU) has a market capitalisation of $ 23 Mln as on 21-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Celularity Inc Class A (CELU)?
Before investing in Celularity Inc Class A (CELU), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.